LB-3. Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhoea incidence rates in one region of Quebec, Canada
Session: Oral Abstract Session: Late Breaker Oral Abstracts
Saturday, October 7, 2017: 10:50 AM
Room: 02

Background: Due to a persistent increase of serogroup B Neisseria meningitidis (Nm) invasive infections in the Saguenay-Lac-Saint-Jean (SLSJ) region of the province of Quebec (Canada) since 2006, a wide-scale vaccination campaign of individuals aged 6 months to 20 years was conducted between May and December 2014 using the 4-component protein-based meningococcus serogroup B vaccine (4CMenB). Components of this vaccine have shown to potentially cross-react with Neisseria gonorrhoeae (Ng). The study objective is to assess the impact of the vaccination campaign on Ng incidence rate (IR).

Methods: Ng cases notified to public health authorities during pre-vaccination period (January 2006 to June 2014) and post-vaccination period (July 2014 to June 2017) were analyzed. The impact of this mass campaign was estimated by a Poisson regression model including the year (11 July-June categories), age (14-20 vs 21 years and older) and the intervention (0 by default and 1 in those 14-20 years in the period of July 2014 to June 2017).

Results: Overall vaccine coverage was 82% in the target group.  A total of 231 Ng cases were reported among persons 14 years and older (IR: 8.4/100,000 person-years) of the SLSJ region from January 2006 to June 2017. A decrease in Ng number of cases and IR among individuals 14-20 years was observed during the post-vaccination period whereas it increased in those 21 years and older (Figure). Estimate of vaccination impact was a Ng risk reduction of 59% (95% CI: -22% to 84%; p = 0.1). During the same period, Chlamydia trachomatis (Ct) infections increased among persons of both age groups in the SLSJ region.   

Conclusion: Although the estimate of the impact of the campaign was not statistically significant, possibly due to limited size of the study population and the low incidence of the disease, it is congruent with results of a case-control study in New Zealand showing an OMV-MeNZB vaccine effectiveness of 31%. A higher effectiveness of 4CMenB is a plausible hypothesis as three additional proteins also found in Ng are included in the vaccine used in SLSJ region. The results of this ecologic study suggest cross-protection of 4CMenB vaccine against Ng infections. Further studies on this topic are warranted.

Figure. Ng and Ct infections per quarter and by age group, SLSJ, January 2006 to June 2017.

Jean Longtin, MD1,2, Rejean Dion, MD1, Marc Simard, M.Sc.1, Jean-Francois Betala Belinga, MD3, Yves Longtin, MD4, Brigitte Lefebvre, PhD1, Annie-Claude Labbé, MD5, Genevieve Deceuninck, MD, MSc1 and Philippe De Wals, MD, PhD1,6, (1)INSPQ, Montreal, QC, Canada, (2)Centre de recherche en infectiologie Université Laval, Quebec, QC, Canada, (3)CISSS du Saguenay-Lac-Saint-Jean, Saguenay, QC, Canada, (4)Infectious Diseases & Microbiology, Jewish General Hospital, Montreal, QC, Canada, (5)Microbiology, CIUSSS de l’est-de-l’île-de-Montréal, Montreal, QC, Canada, (6)Social and Preventive Medicine, Laval University, Quebec City, QC, Canada

Disclosures:

J. Longtin, None

R. Dion, None

M. Simard, None

J. F. Betala Belinga, None

Y. Longtin, None

B. Lefebvre, None

A. C. Labbé, None

G. Deceuninck, None

P. De Wals, GlaxoSmithKline: Grant Investigator and Scientific Advisor , Grant recipient and travel expenses
Pfizer: Grant Investigator and Scientific Advisor , Grant recipient and travel expenses
Sanofi-Pasteur: Grant Investigator and Scientific Advisor , Grant recipient and travel expenses
Novartis: Grant Investigator and Scientific Advisor , Grant recipient and travel expenses

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.